Page last updated: 2024-11-11

cilobradine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cilobradine: has bradycardic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9869877
CHEMBL ID1436376
SCHEMBL ID628133
MeSH IDM0473018

Synonyms (15)

Synonym
gtpl2355
3-[[(3s)-1-[2-(3,4-dimethoxyphenyl)ethyl]piperidin-3-yl]methyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one
dk-ah269
cilobradine
NCGC00165786-01
unii-5o1ll04gj3
cilobradine [inn]
147541-45-5
5o1ll04gj3 ,
(+)-(s)-3-((1-(3,4-dimethoxyphenethyl)-3-piperidyl)methyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2h-3-benzazepin-2-one
2h-3-benzazepin-2-one, 3-((1-(2-(3,4-dimethoxyphenyl)ethyl)-3-piperidinyl)methyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, (s)-
2h-3-benzazepin-2-one, 3-(((3s)-1-(2-(3,4-dimethoxyphenyl)ethyl)-3-piperidinyl)methyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-
SCHEMBL628133
CHEMBL1436376
Q27076054

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"To evaluate the population pharmacokinetic characteristics of cilobradine including a covariate analysis based on six phase I trials and to assess the predictive performance of the model developed."( Population Pharmacokinetic Data Analysis of Cilobradine, an I f Channel Blocker.
Fliss, G; Kloft, C; Schaefer, HG; Staab, A; Tillmann, C; Trommeshauser, D, 2008
)
0.85

Dosage Studied

ExcerptRelevanceReference
" Therefore, the model can serve as a tool to simulate and evaluate different dosing regimens for further clinical trials."( Population Pharmacokinetic Data Analysis of Cilobradine, an I f Channel Blocker.
Fliss, G; Kloft, C; Schaefer, HG; Staab, A; Tillmann, C; Trommeshauser, D, 2008
)
0.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00320.003245.467312,589.2998AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1346522Human HCN3 (Cyclic nucleotide-regulated channels)2006Molecular pharmacology, Apr, Volume: 69, Issue:4
Bradycardic and proarrhythmic properties of sinus node inhibitors.
AID1346525Human HCN1 (Cyclic nucleotide-regulated channels)2006Molecular pharmacology, Apr, Volume: 69, Issue:4
Bradycardic and proarrhythmic properties of sinus node inhibitors.
AID1346524Human HCN2 (Cyclic nucleotide-regulated channels)2006Molecular pharmacology, Apr, Volume: 69, Issue:4
Bradycardic and proarrhythmic properties of sinus node inhibitors.
AID1346517Human HCN4 (Cyclic nucleotide-regulated channels)2006Molecular pharmacology, Apr, Volume: 69, Issue:4
Bradycardic and proarrhythmic properties of sinus node inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (46.15)29.6817
2010's5 (38.46)24.3611
2020's2 (15.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.50 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]